Clinical Care Options Breast Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Breast Cancer: A Review of Key Clinical Studies
Learning Module - Review the latest developments in breast cancer care from ASCO 2017 with these expert insights from Sara Hurvitz, MD, FACP, and Kathy D. Miller, MD. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - August 16, 2017 Category: Cancer & Oncology Source Type: research

Phase III PlanB Final Analysis: Adjuvant TC vs EC & #8594;T in Pts With High-Risk HER2-Negative Early Breast Cancer
Slideset - TC noninferior to EC→T in patients with high-risk HER2-negative early BC with comparable 5-year DFS (90%), OS (95%), and reduced toxicity. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 12, 2017 Category: Cancer & Oncology Source Type: research

I-SPY 2: Addition of Pembrolizumab to Neoadjuvant Chemotherapy in HER2-Negative Early Breast Cancer
Slideset - The addition of pembrolizumab to neoadjuvant T→ AC “graduated” I-SPY 2 for efficacy, approximately tripling the estimated pCR in TNBC and in HR+/HER2- EBC. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 9, 2017 Category: Cancer & Oncology Source Type: research

TRAIN-2 (BOOG 2012-03): Phase III Trial of Neoadjuvant Chemotherapy ± Anthracyclines With Dual HER2 Blockade in HER2+ EBC
Slideset - Comparable pCR, less febrile neutropenia and LVEF decline with anthracycline-free vs anthracycline-containing neoadjuvant CT when paired with dual HER2 blockade. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 9, 2017 Category: Cancer & Oncology Source Type: research

Targeting CDK4/6 in Patients With Cancer
Slideset - The first of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review critical data on the mechanisms of CDK4/6 inhibition and its clinical effects in various cancer types. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 8, 2017 Category: Cancer & Oncology Source Type: research

Phase III SOLE: Continuous vs Intermittent Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer
Slideset - Extended intermittent letrozole did not improve DFS or other efficacy outcomes compared with continuous dosing. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 8, 2017 Category: Cancer & Oncology Source Type: research

OlympiAD: PARP Inhibitor Olaparib Monotherapy in HER2-Negative, < i > BRCA < /i > -Mutated MBC
Slideset - Study data showed significantly prolonged PFS and a lower rate of high-grade adverse events with olaparib monotherapy vs CT. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 8, 2017 Category: Cancer & Oncology Source Type: research

Combination Approaches and Extending the Use of CDK4/6 Inhibitors Beyond ER-Positive Breast Cancer
Slideset - The third of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review key data on combining CDK4/6 inhibitors with hormone therapy, PI3K inhibitors, and others in multiple cancers. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 8, 2017 Category: Cancer & Oncology Source Type: research